• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

工程化细胞因子疗法

Engineering cytokine therapeutics.

作者信息

Deckers Jeroen, Anbergen Tom, Hokke Ayla M, de Dreu Anne, Schrijver David P, de Bruin Koen, Toner Yohana C, Beldman Thijs J, Spangler Jamie B, de Greef Tom F A, Grisoni Francesca, van der Meel Roy, Joosten Leo A B, Merkx Maarten, Netea Mihai G, Mulder Willem J M

机构信息

Department of Internal Medicine and Radboud Center for Infectious diseases (RCI), Radboud University Medical Centre, Nijmegen, Netherlands.

Laboratory of Chemical Biology, Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, Netherlands.

出版信息

Nat Rev Bioeng. 2023;1(4):286-303. doi: 10.1038/s44222-023-00030-y. Epub 2023 Feb 16.

DOI:10.1038/s44222-023-00030-y
PMID:37064653
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9933837/
Abstract

Cytokines have pivotal roles in immunity, making them attractive as therapeutics for a variety of immune-related disorders. However, the widespread clinical use of cytokines has been limited by their short blood half-lives and severe side effects caused by low specificity and unfavourable biodistribution. Innovations in bioengineering have aided in advancing our knowledge of cytokine biology and yielded new technologies for cytokine engineering. In this Review, we discuss how the development of bioanalytical methods, such as sequencing and high-resolution imaging combined with genetic techniques, have facilitated a better understanding of cytokine biology. We then present an overview of therapeutics arising from cytokine re-engineering, targeting and delivery, mRNA therapeutics and cell therapy. We also highlight the application of these strategies to adjust the immunological imbalance in different immune-mediated disorders, including cancer, infection and autoimmune diseases. Finally, we look ahead to the hurdles that must be overcome before cytokine therapeutics can live up to their full potential.

摘要

细胞因子在免疫中发挥着关键作用,这使得它们作为多种免疫相关疾病的治疗手段具有吸引力。然而,细胞因子在临床上的广泛应用受到其血液半衰期短以及低特异性和不良生物分布所导致的严重副作用的限制。生物工程学的创新有助于推进我们对细胞因子生物学的认识,并产生了用于细胞因子工程的新技术。在本综述中,我们讨论了生物分析方法的发展,如测序和与基因技术相结合的高分辨率成像,如何促进了对细胞因子生物学的更好理解。然后,我们概述了细胞因子重新设计、靶向和递送、mRNA治疗和细胞治疗所产生的治疗方法。我们还强调了这些策略在调节不同免疫介导疾病(包括癌症、感染和自身免疫性疾病)中的免疫失衡方面的应用。最后,我们展望了细胞因子治疗充分发挥其潜力之前必须克服的障碍。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f606/9933837/c6bf78f5de1b/44222_2023_30_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f606/9933837/78445d620f4a/44222_2023_30_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f606/9933837/2b6e442f2b88/44222_2023_30_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f606/9933837/2dee7e238696/44222_2023_30_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f606/9933837/c6bf78f5de1b/44222_2023_30_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f606/9933837/78445d620f4a/44222_2023_30_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f606/9933837/2b6e442f2b88/44222_2023_30_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f606/9933837/2dee7e238696/44222_2023_30_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f606/9933837/c6bf78f5de1b/44222_2023_30_Fig4_HTML.jpg

相似文献

1
Engineering cytokine therapeutics.工程化细胞因子疗法
Nat Rev Bioeng. 2023;1(4):286-303. doi: 10.1038/s44222-023-00030-y. Epub 2023 Feb 16.
2
Engineering interferons and interleukins for cancer immunotherapy.工程干扰素和白细胞介素用于癌症免疫治疗。
Adv Drug Deliv Rev. 2022 Mar;182:114112. doi: 10.1016/j.addr.2022.114112. Epub 2022 Jan 24.
3
Cytokine engineering for targeted cancer immunotherapy.细胞因子工程靶向癌症免疫治疗。
Curr Opin Chem Biol. 2021 Jun;62:43-52. doi: 10.1016/j.cbpa.2021.01.007. Epub 2021 Mar 6.
4
Overcoming Pharmaceutical Bottlenecks for Nucleic Acid Drug Development.克服核酸药物开发中的制药瓶颈
Acc Chem Res. 2023 Feb 7;56(3):224-236. doi: 10.1021/acs.accounts.2c00464. Epub 2023 Jan 9.
5
Fc-based cytokines : prospects for engineering superior therapeutics.基于Fc的细胞因子:构建卓越疗法的前景
BioDrugs. 2008;22(1):11-26. doi: 10.2165/00063030-200822010-00002.
6
Recent and future perspectives on engineering interferons and other cytokines as therapeutics.近期和未来展望:工程干扰素和其他细胞因子作为治疗药物的前景。
Trends Biochem Sci. 2023 Mar;48(3):259-273. doi: 10.1016/j.tibs.2022.09.005. Epub 2022 Oct 11.
7
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
8
Functionalized bioengineered spider silk spheres improve nuclease resistance and activity of oligonucleotide therapeutics providing a strategy for cancer treatment.功能化生物工程蜘蛛丝球体提高核酸酶抗性和寡核苷酸疗法的活性,为癌症治疗提供了一种策略。
Acta Biomater. 2017 Sep 1;59:221-233. doi: 10.1016/j.actbio.2017.07.014. Epub 2017 Jul 8.
9
Bacterially mediated drug delivery and therapeutics: Strategies and advancements.细菌介导的药物递送与治疗:策略与进展
Adv Drug Deliv Rev. 2022 Aug;187:114363. doi: 10.1016/j.addr.2022.114363. Epub 2022 May 29.
10
Synthetic Biology and Engineered Live Biotherapeutics: Toward Increasing System Complexity.合成生物学与工程化活体生物疗法:朝着增加系统复杂性的方向发展。
Cell Syst. 2018 Jul 25;7(1):5-16. doi: 10.1016/j.cels.2018.06.008.

引用本文的文献

1
Biomaterials nanoplatform-based tumor vaccines for immunotherapy.基于生物材料纳米平台的肿瘤免疫治疗疫苗
Bioact Mater. 2025 Jun 30;51:924-961. doi: 10.1016/j.bioactmat.2025.06.038. eCollection 2025 Sep.
2
The biology of interleukin-6 family cytokines is regulated by glycosylation.白细胞介素-6家族细胞因子的生物学特性受糖基化作用调控。
Biochem J. 2025 May 21;482(10):535-551. doi: 10.1042/BCJ20240769.
3
Analysis of In Silico Properties and In Vitro Immunomodulatory Effects of Seven Synthetic Host Defence Peptides in Gilthead Seabream (Sparus aurata) Leucocytes.

本文引用的文献

1
Imaging the Alternatively Spliced D Domain of Tenascin C in a Preclinical Model of Inflammatory Bowel Disease.在炎症性肠病的临床前模型中对 tenascin C 的选择性拼接 D 结构域进行成像。
Mol Imaging Biol. 2023 Apr;25(2):314-323. doi: 10.1007/s11307-022-01758-6. Epub 2022 Jul 29.
2
Masking the immunotoxicity of interleukin-12 by fusing it with a domain of its receptor via a tumour-protease-cleavable linker.通过将白细胞介素-12 与其受体的一个结构域融合,并使用肿瘤蛋白酶可切割的连接子进行修饰,从而掩盖其免疫毒性。
Nat Biomed Eng. 2022 Jul;6(7):819-829. doi: 10.1038/s41551-022-00888-0. Epub 2022 May 9.
3
The clinical progress of mRNA vaccines and immunotherapies.
七种合成宿主防御肽在金头鲷(Sparus aurata)白细胞中的计算机模拟性质及体外免疫调节作用分析
Mar Biotechnol (NY). 2025 Jul 12;27(4):109. doi: 10.1007/s10126-025-10488-z.
4
Engineering Fusion Proteins for Nanomedicine-Based Cytokine Therapy.用于基于纳米医学的细胞因子治疗的工程融合蛋白
Bioconjug Chem. 2025 Aug 20;36(8):1698-1708. doi: 10.1021/acs.bioconjchem.5c00182. Epub 2025 Jul 11.
5
Activity-attenuated serum albumin-fused interleukin-33 suppresses experimental autoimmune encephalomyelitis.活性减弱的血清白蛋白融合白细胞介素-33可抑制实验性自身免疫性脑脊髓炎。
Cell Rep Med. 2025 Jul 15;6(7):102231. doi: 10.1016/j.xcrm.2025.102231. Epub 2025 Jul 7.
6
Nanoparticle approaches for manipulating cytokine delivery and neutralization.用于调控细胞因子递送与中和的纳米颗粒方法。
Front Immunol. 2025 Jun 10;16:1592795. doi: 10.3389/fimmu.2025.1592795. eCollection 2025.
7
Trapzyme as multimodal Janus nanoplatform for apoptosis-based immunotherapy of periodontitis.Trapzyme作为用于基于细胞凋亡的牙周炎免疫治疗的多模态Janus纳米平台。
Bioact Mater. 2025 Jun 6;52:139-154. doi: 10.1016/j.bioactmat.2025.05.029. eCollection 2025 Oct.
8
Long-acting IL-2 release from pressure-fused biomineral tablets promotes antitumor immune response.压力融合生物矿物质片剂长效释放白细胞介素-2可促进抗肿瘤免疫反应。
Nat Cancer. 2025 Jun 10. doi: 10.1038/s43018-025-00993-4.
9
Combining local cytokine delivery and systemic immunization with recombinant artLCMV boosts antitumor efficacy in several preclinical tumor models.将局部细胞因子递送与重组artLCMV进行全身免疫相结合,可提高多种临床前肿瘤模型的抗肿瘤疗效。
Oncoimmunology. 2025 Dec;14(1):2514040. doi: 10.1080/2162402X.2025.2514040. Epub 2025 Jun 10.
10
Association between adiposity distribution and high-sensitivity C-reactive protein, adipokines, interleukins and plasminogen activator inhibitor-1.肥胖分布与高敏C反应蛋白、脂肪因子、白细胞介素及纤溶酶原激活物抑制剂-1之间的关联
Int J Obes (Lond). 2025 Jun 3. doi: 10.1038/s41366-025-01816-3.
mRNA 疫苗和免疫疗法的临床进展。
Nat Biotechnol. 2022 Jun;40(6):840-854. doi: 10.1038/s41587-022-01294-2. Epub 2022 May 9.
4
CyTOF for the Masses.流式细胞术大众化。
Front Immunol. 2022 Apr 14;13:815828. doi: 10.3389/fimmu.2022.815828. eCollection 2022.
5
IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines.白细胞介素 1 和白细胞介素 1 受体拮抗剂是 RNA 疫苗引发炎症反应的关键调节因子。
Nat Immunol. 2022 Apr;23(4):532-542. doi: 10.1038/s41590-022-01160-y. Epub 2022 Mar 24.
6
Facile discovery of surrogate cytokine agonists.替代细胞因子激动剂的简便发现。
Cell. 2022 Apr 14;185(8):1414-1430.e19. doi: 10.1016/j.cell.2022.02.025. Epub 2022 Mar 23.
7
Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy.使用脂质纳米粒瘤内递送 IL-12 和 IL-27 mRNA 进行癌症免疫治疗。
J Control Release. 2022 May;345:306-313. doi: 10.1016/j.jconrel.2022.03.021. Epub 2022 Mar 14.
8
Interleukin-2 superkines by computational design.通过计算设计的白细胞介素-2 超家族。
Proc Natl Acad Sci U S A. 2022 Mar 22;119(12):e2117401119. doi: 10.1073/pnas.2117401119. Epub 2022 Mar 16.
9
Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine.先天免疫和适应性免疫对辉瑞-生物科技 BNT162b2 疫苗的作用机制。
Nat Immunol. 2022 Apr;23(4):543-555. doi: 10.1038/s41590-022-01163-9. Epub 2022 Mar 14.
10
Clinically translatable cytokine delivery platform for eradication of intraperitoneal tumors.用于消除腹腔内肿瘤的临床可转化细胞因子递药平台。
Sci Adv. 2022 Mar 4;8(9):eabm1032. doi: 10.1126/sciadv.abm1032. Epub 2022 Mar 2.